Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Do Human Leukocyte Antigen-Typed Cellular Therapeutics Based on Induced Pluripotent Stem Cells Make Commercial Sense?

22 Sept 2014

Abstract excerpt

The promise of off-the-shelf cellular therapeutics (CTPs) based on allogeneic induced pluripotent stem cells (iPSCs) may be hindered by alloimmunity, leading many to suggest that such products could be based on a series of human leukocyte antigen (HLA)-typed iPSC lines allowing at least some degree of tissue matching. While based on sound scientific principles, this suggestion presupposes that other immune...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Pluripotent Stem Cells Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25244598
DOI: 10.1089/scd.2014.0136

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Do Human Leukocyte Antigen-Typed Cellular Therapeutics Based on Induced Pluripotent Stem Cells Make Commercial Sense?PMID 25244598Read ↗

Translational Prospects for Human Induced Pluripotent Stem CellsSemantic proximity Read ↗

Regulatory Considerations for the Development of Autologous Induced Pluripotent Stem Cell TherapiesSemantic proximity Read ↗

Pluripotent stem cell-based immunotherapy: advances in translational research, cell differentiation, and gene modificationsSemantic proximity Read ↗

Roadblocks in the Path of iPSC to the ClinicSemantic proximity Read ↗

Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell TherapySemantic proximity Read ↗

Inducible pluripotent stem cells: not quite ready for prime time?Semantic proximity Read ↗

Engineered T cells from induced pluripotent stem cells: from research towards clinical implementationSemantic proximity Read ↗

‘Off the shelf’ immunotherapies: Generation and application of pluripotent stem cell‐derived immune cellsSemantic proximity Read ↗

Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and ChallengesSemantic proximity Read ↗

An introduction to induced pluripotent stem cellsSemantic proximity Read ↗

Setting Up a Haplobank: Issues and SolutionsSemantic proximity Read ↗

Immunogenicity of induced pluripotent stem cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.